Allograft-Prosthetic Composite (APC) Reconstruction

An allograft-prosthetic composite combines a massive structural allograft (proximal femur, proximal tibia, proximal humerus or an intercalary segment) with a conventional or long-stemmed prosthesis. The prosthesis provides the articulation; the allograft provides:

• Bone stock restoration — critical in young patients who will require future revision. A failed APC usually leaves more bone than a failed megaprosthesis.
• Soft-tissue attachment sites — the decisive functional advantage over a megaprosthesis:
  • Proximal femur: host abductor tendon repaired to the allograft's retained abductor tendon and greater trochanter — better gait, less Trendelenburg lurch, potentially lower dislocation risk.
  • Proximal tibia: host patellar tendon sutured to the allograft's retained patellar tendon — biological extensor mechanism reconstruction, superior to tendon-to-metal fixation.
  • Proximal humerus: host rotator cuff, capsule and remaining tuberosity tissue repaired to allograft cuff stumps — restores stability and some active motion.
• Modularity of philosophy — biological reconstruction at the junction and soft tissues; mechanical reliability of a prosthetic articulation (avoiding the cartilage degeneration and joint instability of osteoarticular allografts, which APCs have largely superseded at the knee and shoulder).

Trade-offs: longer operating time, dependence on bone bank availability and size matching, junction union required before full loading (delayed rehabilitation compared with megaprosthesis), and late allograft-specific complications (fracture, resorption, infection of dead bone).

• Source: accredited musculoskeletal tissue bank; cadaveric donor screened by serology (HIV, hepatitis B and C, HTLV, syphilis) and culture per national tissue regulations (in the UK, Human Tissue Authority licensing; in the USA, FDA/AATB standards; EU tissue directives elsewhere).
• Preservation: fresh-frozen at minus 80 degrees Celsius is the standard for structural grafts — freezing reduces immunogenicity while largely preserving mechanical strength. Freeze-dried grafts are brittle when rehydrated and unsuitable for major structural roles.
• Irradiation: gamma irradiation above roughly 25 kGy significantly weakens cortical bone (dose-dependent loss of bending and torsional strength and fatigue life). Avoid high-dose irradiated grafts for structural APC segments; low-dose or non-irradiated aseptically processed grafts are preferred.
• Size matching: match on calibrated radiographs or CT of donor and host — canal diameter (to accept the stem plus a 2 mm cement mantle), cortical diameter at the planned junction, and segment length. A slightly larger allograft cortex can be telescoped or step-cut over host bone; a smaller graft is harder to salvage.
• Soft-tissue retention: request the graft with retained tendon stumps — abductor tendon and trochanter (femur), patellar tendon (tibia), rotator cuff insertions (humerus) — these are the anchor points for tendon-to-tendon repair.
• Theatre preparation: thaw in warm antibiotic saline, take culture swabs before implantation, ream and lavage the allograft canal to remove marrow elements (reduces immunogenic load and prepares for cement), fashion the osteotomy on the back table against trial components.

Fixation strategies (often combined):

1. Compression plating across the junction — a long plate (often lateral) with bicortical screws in host and allograft, applying interfragmentary compression; add autogenous iliac crest or reamer aspirate graft around the junction. The plate neutralises torsion that a stem alone controls poorly.
2. Long cemented stem bridging the junction — the stem crosses from prosthesis through the entire allograft into host bone, splinting the junction and protecting the graft against fracture; cement is confined to the allograft (and host if chosen) — avoid cement extruding into the junction itself, which blocks union.
3. Combination construct — long stem plus junction plate is common in the lower limb; biomechanically the most stable and increasingly the default for proximal femoral and tibial APCs.

• Aseptic loosening or stem failure with united junction: the united allograft has become part of the host skeleton — revise the prosthetic side alone with a longer stem through the retained allograft shell. This scenario is the payoff of the APC philosophy: bone stock has been banked.
• Junction nonunion with intact implant: compression plating and autografting; exchange to a longer bridging stem if the existing stem is short or loose.
• Allograft fracture: plating and grafting if the segment is salvageable; otherwise revision to a new APC (young patient, allograft available) or conversion to megaprosthesis.
• Infection: staged — remove prosthesis and allograft (dead bone cannot be sterilised), antibiotic spacer, targeted systemic antibiotics, then reconstruct with megaprosthesis, new APC (selected cases after confirmed eradication), arthrodesis, or amputation for uncontrolled sepsis or recalcitrant infection.
• Failed osteoarticular allograft converting to APC: if the original allograft-host junction has united, resurface through the allograft with a stemmed prosthesis — a well-described salvage that preserves the united segment.

Massive allografts unite to host at the junction like a fracture, but the graft itself revascularises only superficially and slowly (creeping substitution limited to the outer millimetres over years). The bulk remains dead scaffold indefinitely — hence late fracture risk and the rationale for a protective intramedullary stem.

• Global epidemiology and practice variation: APC use tracks the availability of accredited musculoskeletal tissue banks. Well-resourced centres in North America, Europe, Australasia, Japan, Brazil and Argentina (which pioneered large bone-banking programmes) use APCs routinely; in regions without bone banks, megaprostheses, extracorporeally irradiated or pasteurised/liquid-nitrogen-treated autografts (recycled autograft techniques popular in parts of Asia) substitute for allograft.
• Tissue regulation: allograft procurement and processing are governed nationally — Human Tissue Authority licensing in the UK, FDA regulations and American Association of Tissue Banks standards in the USA, EU Tissues and Cells Directives across Europe, Therapeutic Goods Administration frameworks in Australia. Surgeons must know their bank is accredited and grafts serologically screened.
• Society guidance: no society issues an APC-specific guideline; principles are embedded in musculoskeletal oncology consensus practice (ISOLS — International Society of Limb Salvage — meetings and classification of reconstruction failure by Henderson and colleagues, which categorises failures into soft tissue, aseptic loosening, structural, infection and tumour progression and is the standard reporting framework for APC series). AO principles govern junction fixation. BOA/BOOS guidance in the UK directs sarcoma reconstruction to specialist centres, where bone banking is concentrated.
• Registry evidence: national arthroplasty registries (NJR, AJRR, AOANJRR, SHAR, Norwegian, NZJR) capture megaprosthetic and some composite revision constructs only coarsely; APC evidence therefore rests on institutional series and ISOLS multicentre reports rather than registry data — a recognised evidence gap.
• Resource-setting adaptation: where allograft is unavailable, alternatives include megaprosthesis, recycled tumour-bearing autograft (irradiated, pasteurised or frozen) combined with a prosthesis — an "autograft-prosthetic composite" applying identical junction and soft-tissue principles.

• Proximal femur: APC or megaprosthesis? Comparable survivorship in most comparative series; dual-mobility megaprostheses have eroded the dislocation argument for APC, while APC retains the bone-stock argument in the young. No randomised evidence exists or is likely.
• Stem fixation in the host: fully cemented (immediate stability, easier in poor bone) versus press-fit host fixation (easier future revision, biological fixation) — practice varies by centre with no comparative superiority shown.
• Plate, stem, or both at the junction: combined constructs are biomechanically stiffest but add soft-tissue stripping and hardware; some series report equivalent union with a well-fitted compressed junction and long stem alone.
• Step-cut versus transverse osteotomy: theoretical advantages of step-cut are not consistently reflected in union rates; precision of contact and compression may matter more than geometry.
• Reverse shoulder APC: increasingly favoured over anatomical/hemiarthroplasty APC in the proximal humerus, but long-term data on glenoid survival in young tumour patients are limited.
• Role of APC in the era of custom 3D-printed implants: additive-manufactured endoprostheses with porous collars and soft-tissue attachment augments may replicate some APC advantages without allograft-specific risks; comparative data are immature.